Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rebekah Guy

Pain Medicine Boise, ID Medical Doctor

NPI 1154542355 CMS profile 1108159

115 W Main St Ste 201, Beacon Pain Clinic, Boise, ID 83702

Open in the dashboard

General payments

$2,624

63 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rebekah Guy of Boise, ID is reported in the CMS Open Payments database as having received $2,624 across 63 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $145 2
2024 General $37 2
2023 General $131 2
2022 General $73 5
2021 General $1,613 19
2020 General $232 21
2019 General $393 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rebekah Guy
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Rebekah Guy were reported at $145. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Rebekah Guy Pain Medicine median Middle half National median
2019 $393 $506 $144–$1,566 $163
2020 $232 $315 $96–$934 $114
2021 $1,613 $452 $134–$1,237 $132
2022 $73 $475 $124–$1,407 $149
2023 $131 $480 $136–$1,384 $160
2024 $37 $521 $164–$1,511 $164
2025 $145 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neuronetics, Inc. $1,168 1 payment
  2. Biodelivery Sciences International, Inc. $188 18 payments
  3. Merz North America, Inc. $182 4 payments
  4. Galderma Laboratories, L.P. $151 3 payments
  5. Idorsia Pharmaceuticals US Inc $145 3 payments
  6. Vertex Pharmaceuticals Incorporated $122 1 payment
  7. Daiichi Sankyo Inc. $113 1 payment
  8. Amgen Inc. $89 4 payments
  9. Pfizer Inc. $53 3 payments
  10. AbbVie, Inc. $46 2 payments
  11. Other $368 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,456 62 payments
  2. Travel and Lodging $1,168 1 payment
Products named General payments · program years 2019–2025
  1. NEUROSTAR TMS THERAPY $1,168 1 payment
  2. BELBUCA $168 16 payments
  3. QUVIVIQ $145 3 payments
  4. JOURNAVX $122 1 payment
  5. Morphabond ER $113 1 payment
  6. EVENITY $51 2 payments
  7. Prolia $51 2 payments
  8. UBRELVY $46 2 payments
  9. RELISTOR Gastroenterology $38 3 payments
  10. RELISTOR Gastroenterology $38 3 payments
  11. Other $506 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

4,654

Median for Pain Management: 951

Drug cost

$446,124

Median for Pain Management: $26,034

Branded share of claims

44.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 161 $122,889
Ubrelvy Ubrogepant Brand 22 $36,351
Fentanyl Generic 135 $31,485
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 808 $31,135
Xtampza Er Oxycodone Myristate Brand 33 $31,102
Nucynta Er Tapentadol Hcl Brand 24 $28,680
Morphine Sulfate Er Morphine Sulfate Brand 603 $20,661
Oxycodone Hcl Generic 596 $20,538
Nucynta Tapentadol Hcl Brand 22 $20,270
Buprenorphine Generic 66 $18,010

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$78,349

Of which drugs: $1,229

Medicare patients

98

Average age 68

Services billed

1,259

64 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Depression 39%
Diabetes 38%
Chronic kidney disease 27%
COPD 22%
Atrial fibrillation 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml Q9965 Office 17 58 $70
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 18 31 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record